ATYR - aTyr Pharma, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ATYR

ATYR PHARMA, INC.

NASDAQ

$0.53

▼ DOWN 1.13% (-0.01)

KEY STATISTICS

Market Cap$52.95 M

52w High$6.50

52w Low$0.40

Dividend Yield—

Frequency—

P/E-0.86

Volume712.61K

Shares Out.98.05M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Sanjay S. Shukla

COMPENSATION 2026

Salary$638,977

Stock Awards$0

Incentive Plan Pay$210,862

All Other Comp.$11,214

Total$3,456,253

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 7, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$17.00

Target Low$1.00

Target Median$1.25

Target Consensus$5.13

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$2.50M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2019-07-01	Reverse	1:14

PRICE

$0.53 ▼ DOWN 1.13% (−$0.01)

OVERLAYS

About aTyr Pharma, Inc.

https://www.atyrpharma.com ↗

aTyr Pharma, Inc. is a San Diego-based biotherapeutics company developing immunological medicines, including efzofitimod in Phase III for pulmonary sarcoidosis and other ILDs, with additional candidates in preclinical stages.

INDUSTRY

Biotechnology

A PRODUCT ATYR PHARMA, INC. IS KNOWN FOR

Efzofitimod

Efzofitimod, Tyr Pharma's lead candidate for ILDs, is in Phase 3 for pulmonary sarcoidosis (pending FDA discussions) and Phase 2 for systemic sclerosis-related ILD, targeting immune-mediated lung inflammation and scarring.